CP-690,550 Thorough QTc Study

• Drug: CP-690,550
  Single dose 100 mg (5 x 20 mg tablets)
• Drug: Placebo
  Single dose placebo tablets (5 tablets)
• Drug: Moxifloxacin
  Single dose Avelox 400 mg tablet

• Experimental: CP-690,550 100 mg
  Intervention: Drug: CP-690,550
• Placebo Comparator: Placebo
  Intervention: Drug: Placebo
• Active Comparator: Moxifloxacin hydrochloride
  Intervention: Drug: Moxifloxacin

Inclusion Criteria:

• Healthy male and/or female subjects between ages of 18 and 55 years, inclusive.
• Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Use of tobacco- or nicotine-containing products in excess of equivalent of 5 cigarettes per day.
• 12-lead ECG demonstrating QTc >450 msec or other clinically significant abnormalities at Screening.
• History of risk factors for QT prolongation or torsades de pointes.
• Pregnant or nursing women; women of childbearing potential unwilling or unable to use an acceptable method of nonhormonal contraception from at least 14 days prior to first dose until completion of follow-up.
• Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to first dose of trial medication.
• Any clinically significant infections within past 3 months or evidence of infection in past 7 days.